Vincogen Corporation
Monday, February 26, 2024
Uris
Tools/Drug Development Support Tech
Vincogen corporation (www.vincogen.com) is the Biotechnology - Artificial Intelligence company and has developed VincoAI, a collection of generative AI models. VincoAI is the first proof-of-concept generative AI to accurately predict amino acid sequences based on high-quality protein data. Vincogen is focusing on niche markets, an AI based personalized/precision medicine, with superior VincoAI platforms to provide the needs of human beings. Significantly, the company's novel biotechnology is beyond the development stage.
VincoAI
Our technology, VincoAI, is a Large Language Model not trained on language -- but on amino acids binding pairs.
A collection of generative AI models. It is the first Proof-of-Concept peptide-binding Generative AI platform that produces novel peptide sequences (Vinco Peptides) that can bind onto the active or binding sites of targeted AMR proteins.
State
Pennsylvania
Country
United States
Website
https://vincogen.com/
CEO/Top Company Official
Derhsing Lai
Lead Product in Development
The Portfolio of VincoAI Peptides with 109 Specific Targets (list below)
This extensive collection features data of PCC uniquely generated and predicted by VincoAI. We uphold the accuracy of our results using the advanced HPEP Dock 3.0 system. (Vincogen)
Category (Disease) No. of Targets Target proteins
Coagulation disorder................................................6........................TAFI, PAI1, F10, F2, F9, F11,
Autoimmune..............................................................4........................IRAK4, STING1,cGAS, IL23R
AMR virus..................................................................14.......................LSD1, RVFVGP, ZikaNS3, LassaGP, RABVGP, MPOXp37, Mpro, EbolaGP,
NIVGP, HIV gp120, HIV gp41, HCV N3/4A, SARS-CoV-2 Spike, HDAC3
AMR bacteria............................................................17.......................ETA, 50S, LigA (G+), LigA (G-), GyrA (G-), GyrB (G-), Sspa, OXA10 (G-), PilA
(G-), bla-imp13 (G-), Beta-lactamase (G-), TEM1 (G-), EptA (G-), Asd, CNA,
PBP2a, PAPS reductase
AMR fungi....................................................................2......................DHFR, HOM2
Neuro-degeneration (AD,Parkinson ALS)................8......................TTR, Bcl2, Tau, APOE, LRRK2, LSD1, HDAC3, BACE1
Weight loss..................................................................1......................PNLIP
Osteoarthritis..............................................................1......................MMP13
Rare Diseases............................................................17......................TTR, CFD, FGF2, C1s, FGFR2, MASP1, MASP2, IL1B, CEGT, PR3, MPO. IL33,
PMP22, IFNAR2, CFTR, HDAC3, IL6, AQP4
Cancers, Tumors.......................................................28......................CD51, TFPI2, FGF2, FGFR2, IOD1, TIGIT, HER2, LSD1, PD1, CTLA4, PTGS2,
VEGF, VEGFR2, Bcl2, EGFR, CD155, EPHB3, BCMA, STING1, BAFFR, JMJD6,
IGF1R, S1PR1, NECTIN4, HDAC3, AGTR1, LAR, SRC
Anti-aging, Senolytic drug..........................................2......................Bcl2, mTOR
Skin care.......................................................................2......................VAMP2, Sspa
Erectile dysfunction (impotence)..............................1.......................PDE5A
Diabetes.......................................................................4......................PPARG, IL18, IL18R, HDAC3
Inflammatory Diseases............................................14......................FGF2, FGFR2, IL1B, IL18, IL18R, PTGS2 (COX2), IRAK4, STING1, cGAS, IL23R,
RIPK2, IL6, IL6RA
CNS disorder.......................................................................................LSD1
Hair regeneration.......................................................1......................JAK3
Schizophrenia.............................................................1......................PDE10A
Psoriasis......................................................................3......................IFNG, IFNGR, S1PR1
Angiogenesis...............................................................2.....................VEGF, VEGFR2,
Hypercholesterolemia...............................................1.....................PCSK9
Complement diseases...............................................4.....................CFD, C1s, MASP1, MASP2,
Cardiovascular Disease.............................................8.....................IL1B, PCSK9, IL18, IL18R, PTGS2 (COX2), FGF2, HDAC3, AGTR1
Cancer checkpoint immunotherapy........................7.....................CD51, TFPI2, IDO1, TIGIT, PD1, CTLA4, NECTIN4
Sickle cell disease.......................................................3.....................HDAC3, LSD1, PAI1
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
110 unlicensed products, as 109 Vinco peptide Specific Targets and 1 VincoAI
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}